Skip to Content
Merck
All Photos(1)

Key Documents

Y0001047

Teicoplanin for identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Teicoplanin, Targocid, Teichomycin

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

teicoplanin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

InChI

1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66-,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88+/m1/s1

InChI key

BJNLLBUOHPVGFT-QRZIFLFXSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Teicoplanin for identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Teicoplanin is a glycopeptide antibiotic produced by Actinoplanes teichomiceticus that is effective against Gram-positive bacteria resistant to β-lactam antibiotics. Its mechanism of action is through inhibition of bacterial cell wall biosynthesis.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Complex oxidation chemistry in the biosynthetic pathways to vancomycin/teicoplanin antibiotics.
Paul F Widboom et al.
Chembiochem : a European journal of chemical biology, 10(11), 1757-1764 (2009-06-18)
Hyung-Moo Jung et al.
Applied microbiology and biotechnology, 84(3), 417-428 (2009-07-18)
The glycopeptide teicoplanin isolated from the fermentation broth of Actinoplanes teichomyceticus is used to treat serious Gram-positive bacterial infections that are resistant to other antibiotics, e.g. beta-lactams. The long time frame and progressively broader clinical use of teicoplanin has eventually
Hugo Paganini et al.
Medicina, 62 Suppl 2, 52-55 (2002-12-17)
Teicoplanin is a glycopeptide antibiotic with similar spectrum to vancomycin. Its long half-life permits administration in a single daily dose. The adverse effects of teicoplanin are less frequent than those of vancomycin. Rash and local intolerance are the most frequent.
Teicoplanin.
M Salaria
Indian pediatrics, 38(4), 372-375 (2001-04-21)
Francisco Nacinovich et al.
Medicina, 62 Suppl 2, 36-39 (2002-12-17)
Antibiotic prophylaxis has become a standard of care in all surgical categories, since its impact in reducing the incidence of post-operative infections has now been well established. Antibiotic prophylaxis should target expected pathogens. Glycopeptide-based regimens have been considered a choice

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service